1)Aoki A, et al : Clinical significance of interferon-γ neutralizing autoantibodies against disseminated nontuberculous mycobacterial disease. Clin Infect Dis 66(8) : 1239-1245, 2018. PMID 29126235 〈既知の免疫不全を有さない播種性NTM症の多くが、抗IFNγ中和自己抗体を持つことを証明し、予後についても言及している〉
2)Matveychuk A, et al : Clinical and radiological features of Mycobacterium kansasii and other NTM infections. Respir Med 106(10) : 1472-1477, 2012. PMID 22850110 〈M.kasasii症と結核菌の臨床症状と画像での類似点を説明〉
3)Johnston JC, et al : Mycobacterium kansasii. Microbiol Spectr 5(1), 2017. PMID 28185617 〈M. kansasii症の疫学、微生物学、診断、治療を含めた総説〉
4)Wu UI, et al : Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-γ autoantibodies in patents with disseminated nontuberculous mycobacterial infection. Clin Microbiol Infect 24(2) : 159-165, 2018. PMID 28694201 <抗IFN-γ自己抗体陽性のNTM症でのQFT-GIT試験の有用性を説明>
5)Xie YL, et al : Severe paradoxical reaction during treatment of disseminated tuberculosis in a patient with neutralizing anti-IFN-γ autoantibodies. Clin Infect Dis 62(2) : 770-773, 2016. PMID 26646678 〈結核の初期悪化でのIFN-γの必要性を疑問視している〉